What We Learn When Two Ruthless Killers, Heart Disease and Cancer, Reveal a Common Root

h c

If inflammation triggers coronary disease, might targeting it directly — beyond simply reducing cholesterol — decrease the risk of heart attacks? Over the course of a decade, Libby and Ridker found themselves focusing on a molecule involved in inflammation called interleukin-1 beta. By the mid-2000s, they heard of a new drug — an interleukin-1-beta inhibitor — that was used to treat exceedingly rare inflammatory diseases. In April 2011, Ridker’s team started enrolling 10,000 patients who carried signs of inflammation and were at very high risk for coronary disease in a randomized study to determine the effects of the inhibitor on heart disease and strokes.

Read Article:  https://www.nytimes.com/2017/09/27/magazine/can-heart-disease-shed-light-on-cancer.html